With Additional Active Ingredient Patents (Class 514/171)
-
Patent number: 10966930Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.Type: GrantFiled: March 19, 2019Date of Patent: April 6, 2021Assignee: Aragon Pharmaceuticals, Inc.Inventor: Geert Verreck
-
Patent number: 10925863Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.Type: GrantFiled: October 2, 2019Date of Patent: February 23, 2021Assignee: MERCATOR MEDYSTEMS, INC.Inventor: Kirk Patrick Seward
-
Patent number: 10905668Abstract: The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them: wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.Type: GrantFiled: September 28, 2017Date of Patent: February 2, 2021Assignee: BIOGEM S.C. A R.L.Inventors: Claudio Pisano, Sabrina Dallavalle, Raffaella Cincinelli, Lucio Merlini
-
Patent number: 10898495Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.Type: GrantFiled: March 11, 2020Date of Patent: January 26, 2021Assignee: M ET P PHARMA AGInventors: Claudia Mattern, Elisabeth Traiffort, Michael Schumacher
-
Patent number: 10874638Abstract: Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions.Type: GrantFiled: September 16, 2019Date of Patent: December 29, 2020Assignee: Ligand Pharmaceuticals IncorporatedInventor: Lin Zhi
-
Patent number: 10849911Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.Type: GrantFiled: June 8, 2016Date of Patent: December 1, 2020Assignee: Galmed Research and Development Ltd.Inventors: Allen Baharaff, Idit Eshkar-Oren
-
Patent number: 10837971Abstract: Methods are provided for detecting the amount of one or more HRT panel analytes (i.e., estrone (E1), estrone sulfate (E1s), 17?-estradiol (E2a), 17?-estradiol (E2b), estradiol sulfate (E2s), estriol (E3), equilin (EQ), 17?-dihydroequilin (EQa), 17?-dihydroequilin (EQb), Equilenin (EN), 17?-dihydroequilenin (ENa), 17?-dihydroequilenin (ENb), and ?8,9-dehydroestrone (dE1)) in a sample by mass spectrometry. The methods generally involve ionizing one or more HRT panel analytes in a sample and quantifying the generated ions to determine the amount of one or more HRT panel analytes in the sample. In methods where amounts of multiple HRT panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.Type: GrantFiled: August 30, 2016Date of Patent: November 17, 2020Assignee: Quest Diagnostics Investments IncorporatedInventors: Mildred Goldman, Nigel Clarke
-
Patent number: 10835502Abstract: This disclosure relates to a method of reducing a fat deposit comprising injecting an alcohol-containing pharmaceutical composition into the fat deposit. The method may be effective in improving the appearance of or reducing the weight or volume of the fat deposit.Type: GrantFiled: October 15, 2019Date of Patent: November 17, 2020Assignee: Polithera, Inc.Inventors: Adam M. Rotunda, Vince Afsahi
-
Patent number: 10835454Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.Type: GrantFiled: June 22, 2015Date of Patent: November 17, 2020Assignees: Corium, Inc., A.V. Topchiey Institute of Petrochemical Synthesis, Russian Academy of SciencesInventors: Parminder Singh, Adrian Faasse, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir F. Bayramov
-
Patent number: 10813858Abstract: A cosmetic composition is provided, the composition comprising a safe and effective amount of a skin care active with A log P less than ?2.0, a safe and effective amount of a fatty alcohol; and a safe and effective amount of a glyceryl ester. The combination of fatty alcohol and glyceryl esters surprisingly enhances penetration of skin care actives with low A log P values into skin.Type: GrantFiled: September 26, 2019Date of Patent: October 27, 2020Assignee: The Procter & Gamble CompanyInventors: Kunal Virendra Gujraty, Shikhar Gupta, Yan Yan, Naohisa Yoshimi
-
Patent number: 10780097Abstract: This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia. Patients at such high risk may be identified prior to their developing hypokalemia. Such a patient may be an adult patient with endogenous Cushing's Syndrome having type 2 diabetes mellitus or glucose intolerance to control hyperglycemia secondary to hypercortisolism. Patients may be identified by an above-threshold level of ACTH or cortisol in a patient sample taken post-GRM administration or pre-GRM administration, respectively. Upon identifying such a patient prior to the development of low potassium, the present methods provide for prophylactically treating the patient by administration of one or more hypokalemia treatments concurrently with an increased dose of GRM or with an initial dose of GRM to prevent hypokalemia.Type: GrantFiled: August 22, 2018Date of Patent: September 22, 2020Assignee: Corcept Therapeutics, Inc.Inventor: Andreas Moraitis
-
Patent number: 10765684Abstract: The present invention is directed generally to pharmaceutical compositions, methods, and kits for improving side effects associated with aromatase inhibitor treatment in a subject diagnosed with breast cancer. More specifically, the present invention provides compositions, methods, and kits comprising an aromatase inhibitor and an androgenic agent.Type: GrantFiled: May 25, 2018Date of Patent: September 8, 2020Assignee: Havah Therapeutics Pty Ltd.Inventor: Stephen Nigel Birrell
-
Patent number: 10765630Abstract: The present invention is a method of treating enteropathic arthritis in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID), and/or a salt thereof; and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.Type: GrantFiled: March 15, 2019Date of Patent: September 8, 2020Assignee: SEN-JAM PHARMACEUTICAL LLCInventors: Jacqueline Iversen, Thomas A. Dahl
-
Patent number: 10758554Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.Type: GrantFiled: November 5, 2015Date of Patent: September 1, 2020Assignees: SANTEN PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITEDInventors: Yoko Endo, Kyohei Takahashi, Shinya Umezaki
-
Patent number: 10758544Abstract: Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist.Type: GrantFiled: March 14, 2019Date of Patent: September 1, 2020Assignee: CARDIX Therapeutics, LLCInventors: Jin Jean Wang, Gerald J. Yakatan, Ting N. Lin, Jing H. Gao
-
Patent number: 10751297Abstract: Provided herein are compositions and related methods for the treatment of herpes simplex virus (HSV) induced blisters and resulting ulcerative lesions. The composition includes at least one antiviral agent that is a long-chain aliphatic compound, and at least one topical corticosteroid.Type: GrantFiled: July 19, 2019Date of Patent: August 25, 2020Inventor: Kevin Mrohs
-
Compositions comprising acidic extracts of mastic gum and uses thereof for treating optic neuropathy
Patent number: 10751347Abstract: The invention relates to compositions and formulations comprising isolated acidic fraction of mastic gum and uses thereof for treating optic neuropathy conditions.Type: GrantFiled: September 7, 2017Date of Patent: August 25, 2020Assignee: REGENERA PHARMA LTD.Inventors: Zadik Hazan, Andre C. B. Lucassen, Konstantin Adamsky -
Patent number: 10751317Abstract: Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.Type: GrantFiled: October 6, 2015Date of Patent: August 25, 2020Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTEInventors: Catherine Ludlow, Aimee M. Dudley, Zhihao Tan
-
Patent number: 10716797Abstract: The present invention provides bacterial ATP synthase inhibitors such as a compound of formula (I): There are provided compositions and kits using such compounds and inhibitors.Type: GrantFiled: September 20, 2018Date of Patent: July 21, 2020Assignee: SOCPRA SCIENCES ET GÉNIE S.E.C.Inventors: Éric Marsault, François Malouin, Félix Chagnon, Isabelle Guay, Simon Boulanger
-
Patent number: 10702499Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: March 25, 2019Date of Patent: July 7, 2020Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 10695308Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 14, 2018Date of Patent: June 30, 2020Assignee: United Therapeutics CorporationInventor: Michael Wade
-
Patent number: 10688041Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles including pharmaceutical agents that have a low water/aqueous solubility. In some embodiments, a surface coating includes a synthetic polymer having pendant hydroxyl groups on the backbone of the polymer, such as poly(vinyl alcohol) (PVA). Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.Type: GrantFiled: May 3, 2013Date of Patent: June 23, 2020Assignee: Kala Pharmaceuticals, Inc.Inventor: Alexey Popov
-
Patent number: 10682337Abstract: Methods for treating and preventing pyrexia and other diseases in equines such as horses involving administering an oral pharmaceutical formulation containing metamizole are disclosed.Type: GrantFiled: March 2, 2016Date of Patent: June 16, 2020Assignee: Kindred Biosciences, Inc.Inventor: Emily Sundman
-
Patent number: 10675288Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.Type: GrantFiled: April 4, 2016Date of Patent: June 9, 2020Assignee: TherapeuticsMD, Inc.Inventors: Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
-
Patent number: 10646496Abstract: The present invention provides joint use of stain and adrenocortical hormone for preparing a pharmaceutical product for the treatment of chronic subdural hematoma. The pharmaceutical product according to the present invention is capable of accelerating hematoma absorption and improving a therapeutic effect of single oral administration of a statin-based pharmaceutical product, and the dose of the adrenocortical hormone-based pharmaceutical product used is 1/10 of the dose used in a large-dose hormonal therapy.Type: GrantFiled: December 29, 2016Date of Patent: May 12, 2020Inventors: Jianning Zhang, Rongcai Jiang, Dong Wang
-
Patent number: 10632085Abstract: Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5-dihydroxybenzenesulfonic acid are provided. Also provided are methods of treating psoriasis comprising administering crystalline forms of potassium 2,5-dihydroxybenzenesulfonic acid.Type: GrantFiled: April 23, 2018Date of Patent: April 28, 2020Assignee: AmDerma Pharmaceuticals, LLCInventors: Unni Santhosh, Annadurai Marimuthu Senthilkumar, Bodireddy Mohan Reddy, Rajendran Kamala, Mahender Rao Siripragada
-
Patent number: 10618904Abstract: The present invention provides a hydrobromide of methyl 3-[(4s)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazol[1,2-a][1,4]benzodiazepine-4-yl] propionate and its related crystal forms, preparation method and use thereof. The hydrobromide has excellent solubility (>100 mg/ml), which is significantly superior to other currently commercially available or developed salt products, and is especially suitable for the preparation of injections, has relatively good stability in various crystal forms, and has good practical value and market prospects.Type: GrantFiled: December 13, 2016Date of Patent: April 14, 2020Assignee: CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD.Inventors: Haoxi Huang, Guoqing Zhuo, Guoning Shang, Zhen Liang, Ting Chu, Cuicui Chen, Ming Luo, Yingfu Li, Zhonghai Su
-
Patent number: 10617671Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.Type: GrantFiled: March 25, 2019Date of Patent: April 14, 2020Assignee: MENLO THERAPEUTICS INC.Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
-
Patent number: 10596181Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.Type: GrantFiled: July 9, 2019Date of Patent: March 24, 2020Assignee: M ET P PHARMA AGInventors: Claudia Mattern, Elisabeth Traiffort, Michael Schumacher
-
Patent number: 10588912Abstract: The present disclosure is directed to generally methods for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a premenopausal or perimenopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. These methods may also be useful in post-menopausal woman.Type: GrantFiled: October 26, 2018Date of Patent: March 17, 2020Assignee: Havah Therapeutics Pty LtdInventor: Stephen Nigel Birrell
-
Patent number: 10561672Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.Type: GrantFiled: September 13, 2017Date of Patent: February 18, 2020Assignee: GLENMARK SPECIALTY S.A.Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
-
Patent number: 10548862Abstract: Provided is a topical formulation for preventing or treating acne, including a benzenesulfonamide derivative, and a pharmaceutically or cosmetically acceptable excipient. Also provided is a method for preventing or treating acne, including applying the topical formulation on skin of a subject in need thereof.Type: GrantFiled: December 29, 2017Date of Patent: February 4, 2020Assignees: Gongwin Biopharm Holdings Co., Ltd.Inventors: Chuan-Ching Yang, Mao-Yuan Lin, Tai-Jung Wu, Chi-Chiang Tu, Shun-Chi Wu
-
Patent number: 10537585Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: December 18, 2017Date of Patent: January 21, 2020Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.Inventors: Caterina Kreyenborg, Elisabeth Meimberg, Corinna Tissen, Karl-Heinz Bannefeld, Tomer Gold
-
Patent number: 10500176Abstract: The present invention relates to use of a composition comprising D-glyceric acid (DGA), DL-glyceric acid, L-glyceric acid, or hydroxypyruvatic acid and/or their salts or esters. Further, the invention relates to the use of said composition for enhancing direct and indirect mitochondrial metabolism, e.g. the ATP producing electron transport system (ETS), citric acid cycle or tricarboxylic acid cycle, (TCA), and beta oxidation, and also enhancing the shuttling of reducing equivalents from mitochondrial matrix into the cytosol and protein synthesis in the endoplasmic reticulum. Directly related to the above the use of DGA relates also to reducing the formation of reactive oxygen species (ROS). Alleviating, preventing and even healing effects towards extremely wide range of non-communicable diseases materializes.Type: GrantFiled: September 12, 2014Date of Patent: December 10, 2019Assignee: REPLICON HEALTH OYInventors: Petteri Hirvonen, Peter Eriksson, Risto Kaksonen
-
Patent number: 10487093Abstract: This invention relates to antibacterial drug compounds containing a bicyclic core, typically a bicycle in which one of the rings is an oxazolidinone. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the compounds in treating bacterial infections and in methods of treating bacterial infections.Type: GrantFiled: February 8, 2017Date of Patent: November 26, 2019Assignee: Redx Pharma PLCInventors: Ian Cooper, Amanda Lyons, David Orr, James Kirkham, Kevin Blades
-
Patent number: 10463585Abstract: A cosmetic composition is provided, the composition comprising a safe and effective amount of a skin care active with A log P less than ?2.0, a safe and effective amount of a fatty alcohol; and a safe and effective amount of a glyceryl ester. The combination of fatty alcohol and glyceryl esters surprisingly enhances penetration of skin care actives with low A log P values into skin.Type: GrantFiled: April 6, 2018Date of Patent: November 5, 2019Assignee: The Procter & Gamble CompanyInventors: Kunal Virendra Gujraty, Shikhar Gupta, Yan Yan, Naohisa Yoshimi
-
Patent number: 10463640Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.Type: GrantFiled: August 6, 2018Date of Patent: November 5, 2019Assignee: PHARNEXTInventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
-
Patent number: 10463690Abstract: The present invention relates to the use of chlorine dioxide compositions for treating cancerous tumors. The present invention relates to compositions and methods for treating cancerous tumors, including naïve, metastatic and recurrent cancers. The compositions comprise chlorine dioxide in an effective amount, which is injected into the cancerous tumor at least once, and often at least several times over the course of treatment. The chlorine dioxide compositions are injected directly into the cancerous tumor and the resulting tumor is effectively eliminated from the patient or subject over a period of one to several days to a few weeks, often after a single injection, or multiple injections at one session into the tumor. Often, an initial injection or multiple injections at one session are sufficient to dissolve the cancerous tumor. Often the cancer is eliminated (as evidenced by no remission) in a period of no more than several days to about two-three months and does not recur.Type: GrantFiled: September 7, 2018Date of Patent: November 5, 2019Inventor: Howard Alliger
-
Patent number: 10456436Abstract: The present invention relates to the use of a compound comprising plant based saponins for regulating and balancing gut microflora in a subject. The present invention also relates to the use of a compound comprising plant based saponins for exerting anti-cancer and anti-inflammatory effects by regulating and balancing the gut microbial ecosystem and providing a healthy epithelial microenvironment in the gut for a subject.Type: GrantFiled: July 8, 2016Date of Patent: October 29, 2019Inventor: Wen Luan Wendy Hsiao
-
Patent number: 10441596Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.Type: GrantFiled: March 3, 2017Date of Patent: October 15, 2019Assignee: The University of ChicagoInventors: Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
-
Patent number: 10441558Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.Type: GrantFiled: August 6, 2018Date of Patent: October 15, 2019Assignee: PHARNEXTInventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
-
Patent number: 10434076Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.Type: GrantFiled: March 17, 2017Date of Patent: October 8, 2019Assignee: AmDerma Pharmaceuticals, LLCInventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Patent number: 10420779Abstract: The present invention relates to a composition appropriate for topical application, containing fusidic acid. The homogeneity of the fusidic acid is 90% to 110% of the suggested fusidic acid content, and the amount of air present in the cream is lower than 5 vol %. Furthermore, the present invention also relates to a method for preparing the composition. First, a placebo cream and a suspension of fusidic acid are prepared, which are subsequently mixed at a temperature above the melting point of the placebo cream.Type: GrantFiled: April 20, 2016Date of Patent: September 24, 2019Assignee: Hyloris Pharmaceuticals SAInventor: Thomas Jacobsen
-
Patent number: 10376510Abstract: Provided are compounds of formula (I), wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl; one of X, Y and W is CH and the two others are N; and Z is H or —C(R1)(R2)(R3). The compounds are inhibitors of isocitrate dehydronenase 2 (IDH2) mutants useful for treating cancer.Type: GrantFiled: July 10, 2014Date of Patent: August 13, 2019Assignee: AGIOS PHARMACEUTICALS, INC.Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins
-
Patent number: 10370356Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapyType: GrantFiled: September 20, 2016Date of Patent: August 6, 2019Assignee: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, David House, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
-
Patent number: 10357492Abstract: The present invention relates to a method of treating motor neuron diseases such as amyotrophic lateral sclerosis (ALS) using levosimendan or its active metabolite (II) as an active ingredient. Levosimendan or its active metabolite (II) are able to relieve the loss of skeletal muscle strength or function associated with motor neuron diseases.Type: GrantFiled: October 14, 2015Date of Patent: July 23, 2019Assignee: Orion CorporationInventor: Ken Lindstedt
-
Patent number: 10350185Abstract: The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation.Type: GrantFiled: March 11, 2014Date of Patent: July 16, 2019Assignee: University of Florida Research Foundation, IncorporatedInventors: Sadasivan Vidyasagar, Paul Okunieff
-
Patent number: 10335368Abstract: The present invention is directed to compositions and methods for delivering a tissue scaffold comprising ultrasound-triggerable agents to an individual.Type: GrantFiled: February 26, 2016Date of Patent: July 2, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Mario L. Fabiilli, Christopher Wilson, Frederic Padilla, Francisco Martin-Saavedra
-
Patent number: 10335454Abstract: The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.Type: GrantFiled: December 18, 2015Date of Patent: July 2, 2019Assignee: HELPERBY THERAPEUTICS LIMITEDInventors: Anthony Coates, Yanmin Hu
-
Patent number: 10322101Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.Type: GrantFiled: April 30, 2018Date of Patent: June 18, 2019Assignee: PHARNEXTInventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin